UK’s NICE Seeks Feedback On Proposed Improvements To Its Processes
Proposals extend the health technology appraisal body's focus beyond final guidance to support for early development and real world performance.
You may also be interested in...
bluebird is "shocked and disappointed" at the draft negative reimbursement decision on Zynteglo in UK but measures outlined in the NICE methods review could change fortunes of gene and cell therapies if taken forward.
Following a Brexit-induced delay over the summer, England's HTA body NICE has come up with a concrete set of proposals that it says will help it “robustly and efficiently” evaluate innovative technologies such as advanced therapies, histology-independent cancer treatments, and technologies for rare diseases. Industry bodies have welcomed the plans, which have just been put out for consultation.
New medicines under evaluation at the European Medicines Agency.